NCT03812393View on ClinicalTrials.gov

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

December 15, 2024

Study Completion Date

December 15, 2024

Conditions
Triple Negative Breast CancerEarly-stage Breast CancerHER2-positive Breast Cancer
Interventions
DRUG

Neratinib

For cycle 1 subjects will receive Neratinib 240mg daily for 21 days. For cycle 2-5, subjects will receive carboplatin AUC of 1.5 and Paclitaxel 80mg/m2 on day one in combination with Neratinib 240mg daily for 21 day.

Trial Locations (1)

38139

West Cancer Center, Germantown

Sponsors

Collaborators (1)

Celcuity Inc
All Listed Sponsors
collaborator

Celcuity Inc

INDUSTRY

collaborator

Puma Biotechnology, Inc.

INDUSTRY

lead

West Cancer Center

OTHER

NCT03812393 - Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast | Biotech Hunter | Biotech Hunter